Regeneron accused of ‘counterfeit’ drug-pricing reporting for stare drug Eylea

The Division of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of counterfeit practices connected the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales within the strategy…
Read More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button